Manfred Lehner

This paper describes the engineering of a molecular switch that controls CARs and transcription factors using an orally available drug, demonstrating tight regulation in vitro and in vivo.

The paper introduces miniCARbids, small human-derived CAR binding domains that show high anti-tumor potency in CAR T cells, outperforming traditional scFvs in some cases.

This paper develops caffeine-responsive switches for CAR T cells, showing they can be controlled by caffeine and effectively clear tumors in mice.

This study shows NK cells influence all phases of cancer immunoediting in B-ALL, promoting resistant clones through selective pressure and identifying LY6E as a marker of poor prognosis.